Press releases

(November 18, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of its public offering of $250 million aggregate principal amount of its 4.250 percent senior notes...

(November 16, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has made an equity investment in -- and secured an exclusive option to purchase -- REVA Medical, Inc., a...

(November 15, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today the launch of a public offering of two series of its senior notes under the Company's existing shelf registration...

(November 12, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Credit Suisse First Boston Healthcare Conference 2004, which is being held November 17-19 in...

(November 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that its subsidiary, Advanced Bionics Corporation of Valencia, California, is resuming worldwide distribution of its...

(November 5, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that its TAXUS™ Express2™ paclitaxel-eluting coronary stent system will be the subject of 15 presentations at...

(November 4, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the CIBC World Markets Fifteenth Annual Healthcare Conference, which is being held November 8-10 in...

and Orlando, FL (November 2, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced interim results from a 200-patient clinical trial to evaluate the effectiveness, safety and...

and Orlando, FL (November 2, 2004)-- Boston Scientific Corporation (NYSE: BSX) today announced results supporting the efficacy of the Enteryx Procedure in relieving the symptoms of...

and Orlando, FL (November 2, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced two-year follow-up data from its ongoing Enteryx Procedure clinical trial for the treatment of...

(November 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) today welcomed an announcement by the Interventional Procedures Advisory Committee (IPAC) of the National Institute for Clinical...

(October 28, 2004) -- Boston Scientific Corporation (NYSE:BSX) today announced that it has launched a full line of mid-urethral sling products for the treatment of female stress urinary...

(October 27, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced the start of enrollment in the ARRIVE 2 registry program, which plans to enroll 5,000 patients at approximately 60...

(October 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that its Board of Directors has authorized the repurchase of up to 50 million shares of the Company's common stock...

(October 19, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for its third quarter ended September 30, 2004. Highlights: Net sales of $1.482 billion, an...

(October 13, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its new coronary...

(October 6, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30, 2004 on Tuesday, October 19,...

and Washington, D.C. (October 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced data supporting safety from three post-market registries associated with its TAXUS™...

and Washington, D.C. (October 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced 30-day safety data from its TAXUS V clinical trial. The trial is assessing the slow-release...

and Washington, D.C. (September 29, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced two-year follow-up data from its TAXUS IV clinical trial. The benefits reported at 12 months...

and Washington, D.C. (September 29, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced two-year follow-up data from its TAXUS II paclitaxel-eluting stent system clinical trial. The...

(September 28, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it will make a special one-time contribution to the Company's U.S. 401(k) Retirement Savings Plan. All...

(September 24, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that its subsidiary, Advanced Bionics Corporation of Sylmar, California, is voluntarily recalling worldwide all...

(September 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events at the Transcatheter Cardiovascular Therapeutics (TCT) conference in...

(September 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has completed its inspection of the Company's Galway, Ireland...

(September 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) today provided an update on the sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for the month of August...

(August 31, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced six-month clinical findings from the European component of its Milestone II Registry. The Company said it has...

(August 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that enrollment has begun in its ATLAS clinical trial. ATLAS is the first trial using Boston Scientific's new Liberté™

(August 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast a conference call providing updates on its business performance for 2004 and sales of its TAXUS™ Express2™...

(August 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its Peripheral Cutting...

(August 23, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its FilterWire EZ Embolic...

(August 19, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved extending the shelf life of its TAXUS Express2...

(August 10, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has made a significant equity investment in Northstar Neuroscience, Inc., a privately held company located in...

(August 5, 2004)

(July 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for its second quarter ended June 30, 2004. Net sales for the second quarter were $1.460 billion as...

(July 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA) to begin its...

(July 21, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2004 on Monday, July 26, at 9:00...

(July 16, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it is expanding its voluntarily worldwide recall to include certain additional units of its TAXUS™ Express2™...

(July 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that enrollment has begun in its clinical trial known as FLAME. This prospective, multi-center, randomized study will...

(July 2, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it is voluntarily recalling nationwide approximately 200 units of its TAXUS™ Express2™ Paclitaxel-Eluting...

(June 30, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2004 on Monday, July 19, at 9:00...

(June 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today the completion of its public offering of $600 million aggregate principal amount of 5.45 percent Senior Notes due June...

(June 22, 2004) - Boston Scientific Corporation (NYSE: BSX) announced today the launch of a public offering of $500 million aggregate principal amount of senior notes, under the Company's existing...

(June 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in Goldman Sachs' 25th Annual Healthcare Conference, which is being held June 7-10 in Dana Point, CA. Larry...

(June 3, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for the...

and Valencia, California (June 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) and Advanced Bionics Corporation, a privately held company located in Valencia, CA, today announced the...

(May 28, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a decision by the U.S. District Court in Wilmington,...

and Paris (May 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced nine-month sub-population data from its TAXUS VI clinical trial. The trial enrolled 448 patients at 44 sites...

and Paris (May 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced nine-month results from its TAXUS VI clinical trial. The trial enrolled 448 patients at 44 sites in Europe,...

(May 24, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has completed enrollment in ARRIVE, a peri-approval registry. ARRIVE was designed to collect and analyze...